patent.fyi
Applications  /  US 2026/0356881
United States Patent Application Publication

US 2026/0356881 A1

Published
Nov 12, 2026
Filed
Jun 19, 2026
Earliest date on the face
Oct 14, 2024
Classification
C07K 1/063
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Sulfonate introduced after assembly

What ifWhat if a cysteine precursor supplies a sulfonate side chain after peptide assembly?
Claim language“glutamic acid, aspartic acid, and derivatives thereof”

Assemble the peptide with a trityl-protected cysteine residue and release it from the resin under acidic conditions that remove the trityl group. Oxidize the liberated thiol to a sulfonic acid with performic acid in a sequence without other oxidation-sensitive residues.

1.1Phosphate supplies side chain acidity

What ifWhat if phosphoserine supplies the acidic side chain for peptide assembly?
Claim language“glutamic acid, aspartic acid, and derivatives thereof”

Couple an N-fluorenylmethoxycarbonyl phosphoserine monomer bearing a benzyl group on the phosphate to the resin-bound chain through its alpha-carboxyl group. Remove the phosphate benzyl group during final acid cleavage using a cleavage mixture formulated for that monomer.

1.2Acid cleaves a tert-butyl ester

What ifWhat if a tert-butyl ester masks the side-chain carboxyl group during peptide assembly?
Claim language“a pillar[6]arene dodeca-methylamine molecule”

Couple N-fluorenylmethoxycarbonyl aspartate or glutamate with its side-chain carboxyl group esterified and its alpha-carboxyl group free for activation. The tert-butyl ester persists through piperidine treatment and cleaves during final treatment with trifluoroacetic acid.

1.2Palladium removes an allyl ester

What ifWhat if a covalent allyl ester masks the side-chain carboxyl group for selective removal on the resin?
Claim language“through hydrogen bonding”

Introduce aspartate or glutamate as an N-fluorenylmethoxycarbonyl monomer with an allyl ester on the side chain and a free alpha-carboxyl group. Treat the assembled resin-bound peptide with a palladium catalyst and an allyl scavenger to expose the side-chain acid before final cleavage.

1.2Light releases the side-chain acid

What ifWhat if a photolabile 2-nitrobenzyl ester masks the side-chain carboxyl group?
Claim language“a pillar[6]arene dodeca-methylamine molecule”

Couple the alpha-carboxyl group of an N-protected aspartate or glutamate monomer bearing a side-chain 2-nitrobenzyl ester. After assembly, irradiate the peptide near 365 nanometers in a shallow solution layer to cleave the ester and release the side-chain acid.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Binding with a smaller macrocycle

Pillar[5]arene bearing ten aminomethyl substituents replaces pillar[6]arene dodeca-methylamine as the hydrogen-bond donor for the glutamic acid side-chain carboxyl group. An aqueous titration uses an alpha-amino-protected, alpha-carboxyl-esterified glutamate reference to isolate binding at the side-chain carboxyl group. The measured association constant sets the starting host concentration for a coupling trial with alpha-amino-protected glutamic acid bearing a free alpha-carboxyl group. Liquid chromatography and tandem mass spectrometry compare the alpha-linked and side-chain-linked products against reference peptides.

Parameter or scale variation

Host loading at three ratios

Three batches each contain 10 mM alpha-amino-protected aspartic acid and carry pillar[6]arene dodeca-methylamine at host-to-amino-acid molar ratios of 0.5:1, 1:1, and 2:1. The batches equilibrate for 30 minutes at 25 °C at the same pH and ionic strength. Each batch supplies the same amount of aspartic acid to a separate portion of glycine-loaded resin under identical coupling conditions. Analysis of the released dipeptides measures conversion and the fraction of beta-linked product at each host loading.

Combination with existing systems

Complex delivery through a flow reactor

A packed-bed solid-phase peptide reactor receives a pre-equilibrated solution of alpha-amino-protected glutamic acid and pillar[6]arene dodeca-methylamine from one reservoir and coupling reagent from another. A mixing tee immediately upstream of the resin bed combines the streams and limits the residence time of the activated building block before it reaches the resin. The feed uses a solvent composition in which a binding assay confirms host association and the resin remains swollen. Product analysis compares alpha-linked and gamma-linked peptide fractions after cleavage and host removal.

Host removal by membrane diafiltration

An aqueous feed contains a cleaved short model peptide and pillar[6]arene dodeca-methylamine released from its acidic side chains. A pH selected from a solution binding titration dissociates the complex before the feed enters a tangential-flow membrane module. A membrane selected by measured rejection retains the free macrocycle and passes the peptide, which is collected in the permeate as fresh buffer replaces the removed liquid. Chromatographic assays track peptide recovery and residual macrocycle in the pooled permeate.

Automated or data-driven variant

Sensor control of host complex preparation

A programmable liquid handler dispenses an acidic amino acid building block, pillar[6]arene dodeca-methylamine, and buffer into a stirred vessel fitted with pH and temperature probes. The controller selects the host dose and equilibration time from a calibration table built from binding measurements in the coupling solvent. It records the actual dose, pH, and temperature for each batch and transfers batches within the calibrated operating limits to a peptide synthesizer. Chromatographic measurements of linkage isomers provide the outcome for each recorded batch.

Specific version of a part

Glutamate with a free alpha-carboxyl

Use L-glutamic acid as the guest and retain the gamma-carboxyl group as the host contact site. Block the alpha-amino group with fluorenylmethoxycarbonyl and retain the alpha-carboxyl group for coupling.

Aspartate with a free alpha-carboxyl

Use L-aspartic acid as the guest and retain the beta-carboxyl group as the host contact site. Install a fluorenylmethoxycarbonyl group on the alpha-amino group and leave the alpha-carboxyl group unesterified.

Ammonium donors at the rim

Combine the amino-functionalized pillar[6]arene and glutamate in water at near-neutral pH. Protonated amines at the macrocycle rim donate hydrogen bonds to the side-chain carboxylate oxygens, and the opposite charges contribute electrostatic attraction.

Coupling to a resin-bound amine

Use an alpha-fluorenylmethoxycarbonyl-protected amino acid–host complex with a free alpha-carboxyl group as the incoming monomer. Activate that carboxyl group for amide formation and couple it to the exposed N-terminal amine of a resin-bound peptide.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0057525 A1
Published
Mar 1, 2018
Filed
May 22, 2017
Class
C07K 1/042
Document BUS 2023/0279045 A1
Published
Sep 7, 2023
Filed
Dec 20, 2022
Class
C07K 1/045
Claim 1
Document A
Document B
1.1(a) an acidic amino acid selected from glutamic acid, aspartic acid, and derivatives thereof; and
1.2(b) a pillar[6]arene dodeca-methylamine molecule associated with a side-chain carboxyl group of the acidic amino acid through hydrogen bonding,
1.3wherein the composition is suitable for use as a building block in peptide synthesis.
Unless noted, coupling was performed by delivering the following coupling solution at 6 mL/min (for approximately 30 seconds). The coupling solution consisted of 1 mmol of Na-Fmoc and side chain protected amino acid dissolved in 2.5 mL of 0.4 M HBTU in DMF and 0.5 mL of DIEA.
A · US 2018/0057525 A1 · ¶ 157
In some embodiments, the process of adding amino acid residues to immobilized peptides comprises, in certain embodiments, exposing activated amino acids 95 to the immobilized peptides as indicated by arrow 90 of FIGS. 2A-2C. In some embodiments, as illustrated FIG. 2A, exposing the immobilized peptides to activated amino acids may result in at least a portion of the activated amino acids being bonded to the immobilized peptides to form newly-bonded amino acid residues.
B · US 2023/0279045 A1 · ¶ 60

An empty cell means only that no passage was reproduced there.

Statements in these documents
Though solid phase peptide synthesis has been used for over 30 years, fast synthesis techniques have not yet been developed.
A · US 2018/0057525 A1 · ¶ 3
Certain embodiments relate to systems and methods which can be used to perform solid phase peptide synthesis quickly while maintaining high yield.
A · US 2018/0057525 A1 · ¶ 4
Though solid phase peptide synthesis has been used for over 30 years, automated solid phase peptide synthesizers that afford a high degree of control over individual coupling reactions and/or minimize side reactions have not yet been developed.
B · US 2023/0279045 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356881 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356881/, SHA-256 5e335de41dc388342975d4c11bc97c9e117c019bf36fb6da2b274cf407ee1ec5
First published
Permanent addresshttps://patent.fyi/US20260356881/
Content fingerprint (SHA-256)5e335de41dc388342975d4c11bc97c9e117c019bf36fb6da2b274cf407ee1ec5
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi